Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Empliciti Market Size Forecast: How Big Could The Market Get By 2030?
Growth throughout the historic period can be ascribed to a growing incidence of multiple myeloma, the constrained effectiveness of conventional chemotherapy, the initial success observed with monoclonal antibody drugs, the expansion of oncology care facilities, and an increase in cancer research investments.
The anticipated growth during the forecast period is linked to the increasing integration of immunotherapy methods, an expanding array of monoclonal antibody candidates under development, improved patient survival rates stimulating demand for sustained treatment, supportive reimbursement policies for biologic cancer therapies, and breakthroughs in the creation of immune-based drugs.
Significant trends expected in the forecast period encompass the widespread use of combination monoclonal antibody treatments, cancer therapies that specifically target the immune system, an evolution towards customized care for multiple myeloma patients, a surge in the application of immunotherapy within oncology, and the increasing uptake of long-term biologic treatment protocols.
Get A Free Sample Report With In-Depth Market Insights:
Empliciti Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The rising incidence of multiple myeloma is projected to fuel the expansion of the empliciti market. This specific cancer affects plasma cells, a form of white blood cell located in the bone marrow, leading to abnormal cell proliferation and potential harm to bones, kidneys, and the immune system. Key factors contributing to the increased occurrence of multiple myeloma include an aging demographic and advancements in diagnostic methods. Empliciti operates by targeting the SLAMF7 protein present on both myeloma and natural killer (NK) cells, thereby strengthening the immune system’s capacity to identify and remove cancerous cells. It further improves NK cell function and encourages antibody-dependent cellular cytotoxicity (ADCC), which aids in decelerating disease progression when used alongside other therapies. As an illustration, in August 2024, the American Cancer Society reported that approximately 35,780 new multiple myeloma cases were diagnosed in the United States in 2024, with 19,520 affecting men and 16,260 affecting women. Furthermore, around 12,540 fatalities are expected, comprising 7,020 men and 5,520 women. Consequently, the growing occurrence of multiple myeloma will stimulate the growth of the empliciti market. The escalating need for targeted cancer treatments is a substantial impetus behind the future expansion of the empliciti market. These specialized therapies are designed to combat cancer cells by pinpointing particular molecular indicators, thereby lessening damage to healthy cells. The increasing interest in targeted cancer therapies stems from progress in precision medicine, a higher incidence of cancer, enhanced treatment effectiveness, and an intensified focus on reducing adverse effects. Empliciti specifically targets SLAMF7, a protein found on multiple myeloma and immune cells, empowering the immune system to combat cancer. This two-pronged method boosts accuracy while safeguarding healthy tissues. For example, in June 2024, data from the Royal College of Radiologists indicated that in 2023, the demand for systemic anti-cancer therapies (SACT), including chemotherapy, saw an increase of 6-8%. Hence, the heightened demand for targeted cancer therapies will propel the growth of the empliciti market.
Empliciti Market Segment Analysis Spotlighting Growth Areas
The empliciti market covered in this report is segmented –
1) By Indication: Active Multiple Myeloma, Smoldering Multiple Myeloma
2) By Drug Class: Monoclonal Antibodies, Immunomodulatory Agents, Proteasome Inhibitors
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Empliciti Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the empliciti market are Bristol-Myers Squibb Company
View The Full Empliciti Market Report:
Empliciti Market Largest Region By Revenue And Market Share
North America was the largest region in the empliciti market in 2025. The regions covered in the empliciti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
